Table 1.

Summary of clinical trials about anti-PD-L1 in ES-SCLC

Trial	Phase	No. of Patients	Treatment	FDA Approval	OS	PFS	ORR (%)	AEs (%)
CASPIAN	III	537	Durvalumab + chemotherapy vs. chemotherapy	Yes	12.9 vs. 10.5 months (HR, 0.71; 95% CI: 0.60-0.86; P=0.0003)	5.1 vs. 5.4 months (HR, 0.78; 95% CI: 0.65-0.94; p=0.0003)	68 vs. 58	Serious AEs 32.5 vs. 36.5
IMpower133	III	403	Atezolizumab + chemotherapy vs. chemotherapy	Yes	12.3 vs. 10.3 months (HR, 0.70; 95% CI: 0.54-0.91; P=0.007)	5.2 vs. 4.3 months (HR, 0.77; 95% CI: 0.62-0.96; p=0.02)	60.2 vs. 64.4	Grade 3/4 AEs 56.6 vs. 56.1
IFCT-1603	II	73	Atezolizumab vs. chemotherapy	Yes	9.5 vs. 8.7 months (HR, 0.84; 95% CI: 0.45-1.58; P=0.60)	1.4 (95% CI: 1.2-1.5) vs. 4.3 (95% CI: 1.5-5.9)	2.3 (95% CI: 0.0-6.8)	Grade 3/4 AEs 4.2 vs. 75

OS: overall survival; PFS: progression-free survival; ORR: objective response rate; AEs: adverse events.